A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

Phase 2TerminatedNCT00073476

Pfizer300 enrolled

Overview

The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

300

Conditions

Stroke

Interventions

traxiprodil (CP-101,606)DRUG

Eligibility

Sex: ALLMin age: 40 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: Males \& females age 40-90 years Enrolled in study within 6 hours of onset of stroke symptoms Willing to sign informed consent form No significant disabilities prior to stroke Exclusion Criteria: Treatment with t-PA (tissue plasminogen activator) Premorbid modified rankin scale score of 2 or more

Locations (29)

Outcomes

Primary Outcomes

No or minimal neurological deficit at last visit

Marked neurological improvement at last visit

Secondary Outcomes

Modified Rankin scale at last visit

Mortality

Safety assessments

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.